NeuroSense CTO granted 200,000 restricted shares

Russek-Blum Niva reported acquisition or exercise transactions in this Form 4 filing.

Rhea-AI Filing Summary

Russek-Blum Niva reported acquisition or exercise transactions in this Form 4 filing.

NeuroSense Therapeutics Ltd. reported that Chief Technology Officer Niva Russek-Blum received a grant of 200,000 Ordinary Shares. These are restricted shares awarded as compensation at a stated price of $0.00 per share, increasing her direct holdings to 467,953 Ordinary Shares after the grant.

The restricted shares vest in equal quarterly installments over a two-year period, starting from the grant date of March 26, 2026, and depend on her continued service with the company. Footnotes note that, to qualify for certain tax benefits under Section 102 of the Israeli Tax Ordinance, securities issued under the company’s 2018 Share Incentive Plan must be registered in the name of a trustee.

Insider Trade Summary

Grant/Award: 200,000 shares

Grant/Award 1 txn

Insider Russek-Blum Niva

Role Chief Technology Officer

Type	Security	Shares	Price	Value
Grant/Award	Ordinary Shares	200,000	$0.00	$0.00

Holdings After Transaction: Ordinary Shares — 467,953 shares (Direct)

Footnotes (2)

1. F1. To qualify for certain tax benefits under Section 102 of the Israeli Tax Ordinance, securities issued to an employee or director in connection with the Issuer's 2018 Share Incentive Plan must be registered in the name of a trustee.
2. F2. The restricted shares vest in equal quarterly installments over a two-year period, commencing on the grant date of March 26, 2026, subject to the Reporting Person's continued service to the Issuer as of such vesting date.

Key Figures

Restricted share grant: 200,000 Ordinary Shares Price per granted share: $0.00 per share Total shares after grant: 467,953 Ordinary Shares +3 more

6 metrics

Restricted share grant 200,000 Ordinary Shares Awarded to CTO Niva Russek-Blum as a grant

Price per granted share $0.00 per share Stated transaction price for the 200,000-share award

Total shares after grant 467,953 Ordinary Shares Russek-Blum’s direct beneficial holdings following the transaction

Vesting period Two years Restricted shares vest quarterly from March 26, 2026

Vesting frequency Equal quarterly installments Time-based vesting schedule for the restricted shares

Section 102 requirement Trustee registration Securities must be registered in trustee’s name for tax benefits

Key Terms

restricted shares, Section 102 of the Israeli Tax Ordinance, 2018 Share Incentive Plan, beneficial ownership, +1 more

5 terms

restricted shares financial

"The restricted shares vest in equal quarterly installments over a two-year period"

Restricted shares are company stock that cannot be sold or transferred immediately because they are subject to legal or contractual limits, such as a required holding period or performance conditions. They matter to investors because these locked-up shares can affect a company’s available stock for trading, future dilution, and insider incentives—imagine a gift that can’t be cashed until certain conditions are met, which changes when and how much supply can suddenly enter the market.

Section 102 of the Israeli Tax Ordinance regulatory

"To qualify for certain tax benefits under Section 102 of the Israeli Tax Ordinance"

2018 Share Incentive Plan financial

"securities issued to an employee or director in connection with the Issuer's 2018 Share Incentive Plan"

beneficial ownership financial

"subject to the Reporting Person's continued service to the Issuer as of such vesting date"

Beneficial ownership means the person or entity that actually enjoys the benefits of owning shares or other assets — such as receiving dividends, voting rights, or price gains — even if the legal title is held in another name. For investors it matters because knowing who truly controls and profits from a company reveals who can influence decisions, exposes potential conflicts of interest or hidden concentration of power, and affects transparency and risk in the stock.

vesting financial

"The restricted shares vest in equal quarterly installments over a two-year period"

Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did NeuroSense Therapeutics (NRSN) report for Niva Russek-Blum?

NeuroSense reported that Chief Technology Officer Niva Russek-Blum received a grant of 200,000 restricted Ordinary Shares. The award is a compensation-related acquisition, not an open-market purchase or sale, and is subject to service-based vesting conditions over a defined period.

How many NeuroSense (NRSN) shares does Niva Russek-Blum hold after this Form 4 transaction?

After the reported grant, Niva Russek-Blum beneficially owns 467,953 Ordinary Shares directly. This total includes the newly awarded 200,000 restricted shares, which will vest over time, subject to her continued service with NeuroSense Therapeutics Ltd. under the specified vesting schedule.

What are the vesting terms of the 200,000 restricted shares granted by NeuroSense (NRSN)?

The 200,000 restricted Ordinary Shares vest in equal quarterly installments over a two-year period beginning March 26, 2026. Each vesting installment is contingent on Niva Russek-Blum’s continued service to NeuroSense Therapeutics as of the applicable vesting date, making this a time-based equity award.

Was there a purchase price for the NeuroSense (NRSN) shares granted to Niva Russek-Blum?

The Form 4 shows the 200,000 Ordinary Shares were granted at a transaction price of $0.00 per share. This indicates a compensation-related stock award rather than an open-market purchase, aligning with a typical equity incentive grant structure for senior executives.

How does Section 102 of the Israeli Tax Ordinance affect this NeuroSense (NRSN) share grant?

Footnotes explain that, to qualify for certain tax benefits under Section 102 of the Israeli Tax Ordinance, securities issued under NeuroSense’s 2018 Share Incentive Plan must be registered in the name of a trustee. This relates to tax treatment and custody, not to whether the grant was made.

Are the 200,000 NeuroSense (NRSN) shares for Niva Russek-Blum held directly or through an entity?

The filing identifies the holdings as direct ownership, with the ownership code marked as “D” for direct. Although Section 102 requires registration in a trustee’s name for tax purposes, the Form 4 still attributes the beneficial ownership to Niva Russek-Blum personally.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 03/30/2026 - 05:32 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Russek-Blum Niva

(Last) (First) (Middle)

C/O NEUROSENSE THERAPEUTICS LTD.

11 HAMENOFIM STREET, BUILDING B

(Street)

HERZLIYA 4672562

(City) (State) (Zip)

ISRAEL

(Country)

2. Issuer Name and Ticker or Trading Symbol
NeuroSense Therapeutics Ltd. [ NRSN ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Technology Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
03/26/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Ordinary Shares(1)	03/26/2026		A		200,000(2)	A	$0	467,953	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. To qualify for certain tax benefits under Section 102 of the Israeli Tax Ordinance, securities issued to an employee or director in connection with the Issuer's 2018 Share Incentive Plan must be registered in the name of a trustee.

2. The restricted shares vest in equal quarterly installments over a two-year period, commencing on the grant date of March 26, 2026, subject to the Reporting Person's continued service to the Issuer as of such vesting date.

	/s/ Niva Russek-Blum	03/30/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)